The opioid crisis has been a devastating issue in the United States, with far-reaching consequences that impact healthcare, the criminal justice system, and the economy. However, a recent study published in Value in Health offers a glimmer of hope and a potential solution. Mindfulness-Oriented Recovery Enhancement (MORE), an innovative therapy developed by Eric Garland, PhD, has shown remarkable results in addressing opioid misuse and chronic pain. The study reveals that MORE not only provides effective treatment but also yields a significant return on investment, with a benefit-to-cost ratio of 12-to-1. This means that for every dollar spent on MORE, there is a potential $12 in economic benefit. Personally, I find this ratio incredibly impressive and a testament to the power of this therapy.
What makes this therapy particularly fascinating is its holistic approach. MORE combines mindfulness techniques, cognitive reappraisal, and savoring practices to address addiction, emotional distress, and chronic pain simultaneously. By teaching individuals to regulate cravings and pain through mindfulness, manage stress and emotions through cognitive reappraisal, and reconnect with natural rewards, MORE aims to restore the brain's capacity for healthy pleasure. This is a unique and innovative way of tackling opioid misuse, as it targets the root causes and helps individuals find alternative, healthier ways to cope.
The study's findings are eye-opening. Over a patient's lifetime, MORE can result in cost savings of over $324,000. This is a substantial amount and highlights the potential impact of this therapy on both individual lives and the broader society. By reducing opioid misuse, MORE can decrease overdose deaths, hospitalizations, and the economic burden on healthcare systems.
One aspect that I find intriguing is the potential for MORE to be implemented on a larger scale. With over 16 successful randomized clinical trials and over 2,500 participants, the therapy has shown its effectiveness. However, the researchers suggest that MORE's true impact could be realized if it were integrated into health systems more widely. This would require support and investment from healthcare organizations, insurers, and policymakers. If MORE becomes a standard part of addiction treatment and primary care, we could potentially intervene earlier and prevent opioid misuse from progressing to more severe addiction.
In my opinion, the economic evaluation of MORE is a crucial step in advocating for its widespread adoption. With a clear demonstration of its cost-effectiveness, MORE has the potential to become a powerful tool in the fight against the opioid crisis. It offers a promising, evidence-based approach that could save lives and reduce the societal burden of opioid misuse. The study's authors rightly emphasize the need for support and investment to make this therapy accessible to those who need it most.
The opioid crisis is a complex issue, but innovative solutions like MORE give us hope for a brighter future. By combining neuroscience, mindfulness, and a holistic approach, we may be able to make a significant impact on this devastating problem. It's time to invest in these innovative therapies and give individuals the tools they need to recover and lead healthier lives.
